Castle Biosciences (CSTL) Assets Average (2019 - 2026)

Castle Biosciences (CSTL) has 8 years of Assets Average data on file, last reported at $563.2 million in Q1 2026.

• Quarterly Assets Average rose 9.04% year-over-year to $563.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $563.2 million (up 9.04% YoY) and the FY2025 annual result came in at $554.9 million, up 12.72% from the prior year.
• Assets Average declined to $563.2 million in Q1 2026 per CSTL's latest filing, from $570.7 million in the prior quarter.
• The five-year high for Assets Average was $570.7 million in Q4 2025, with the low at $426.1 million in Q2 2023.
• Average Assets Average over 5 years is $484.4 million, with a median of $458.1 million recorded in 2022.
• Year-over-year, Assets Average fell 5.98% in 2023 and climbed 17.59% in 2024.
• Castle Biosciences' Assets Average stood at $452.6 million in 2022, then slipped by 1.74% to $444.7 million in 2023, then increased by 17.59% to $522.9 million in 2024, then gained by 9.14% to $570.7 million in 2025, then decreased by 1.31% to $563.2 million in 2026.
• Business Quant data shows CSTL's Assets Average at $563.2 million in Q1 2026, $570.7 million in Q4 2025, and $553.8 million in Q3 2025.